There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Eli Lilly & Co (LLY – Research Report) and ImmunoGen (IMGN – Research Report) with bullish sentiments. Eli Lilly & Co (LLY) In a report released today, Evan Seigerman from BMO Capital reiterated a Buy rating on Eli Lilly & Co, with a price target of $396.00. The company's shares closed last Friday at $301.33. According to TipRanks.
https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-and-immunogen-imgn?utm_source=advfn.com&utm_medium=referral
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Oct 2022 to Nov 2022 Click Here for more ImmunoGen Charts.
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Nov 2021 to Nov 2022 Click Here for more ImmunoGen Charts.